Mono-
chemotherapy has significant side effects and unsatisfactory efficacy, limiting its clinical application. Therefore, a combination of multiple treatments is becoming more common in oncotherapy.
Chemotherapy combined with the induction of ferroptosis is a potential new oncotherapy. Furthermore, polymeric nanoparticles (NPs) can improve the antitumor efficacy and decrease the toxicity of drugs. Herein, a polymeric NP,
mPEG-b-PPLGFc@Dox, is synthesized to decrease the toxicity of
doxorubicin (Dox) and enhance the efficacy of
chemotherapy by combining it with the induction of ferroptosis. First,
mPEG-b-PPLGFc@Dox is oxidized by endogenous H2 O2 and releases Dox, which leads to an increase of H2 O2 by breaking the redox balance. The Fe(II) group of
ferrocene converts H2 O2 into ·OH, inducing subsequent ferroptosis. Furthermore,
glutathione peroxidase 4, a
biomarker of ferroptosis, is suppressed and the lipid peroxidation level is elevated in cells incubated with
mPEG-b-PPLGFc@Dox compared to those treated with Dox alone, indicating ferroptosis induction by
mPEG-b-PPLGFc@Dox. In vivo, the antitumor efficacy of
mPEG-b-PPLGFc@Dox is higher than that of free Dox. Moreover, the loss of
body weight in mice treated
mPEG-b-PPLGFc@Dox is lower than in those treated with free Dox, indicating that
mPEG-b-PPLGFc@Dox is less toxic than free Dox. In conclusion,
mPEG-b-PPLGFc@Dox not only has higher antitumor efficacy but it reduces the damage to normal tissue.